Somatic mutations in the KEAP1 ubiquitin ligase or its substrate NRF2 (NFE2L2) commonly occur in human cancer, resulting in constitutive NRF2-mediated transcription of cytoprotective genes. However, many tumors display high NRF2 activity in the absence of mutation, supporting the hypothesis that alternative mechanisms of pathway activation exist. Previously, we and others discovered that via a competitive binding mechanism, the proteins WTX (AMER1), PALB2 and SQSTM1 bind KEAP1 to activate NRF2. Proteomic analysis of the KEAP1 protein interaction network revealed a significant enrichment of associated proteins containing an ETGE amino acid motif, which matches the KEAP1 interaction motif found in NRF2. Like WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an 'ETGE' motif to displace NRF2, thus inhibiting NRF2 ubiquitination and driving NRF2-dependent transcription. Comparing the spectrum of KEAP1 interacting proteins with the genomic profile of 178 squamous cell lung carcinomas characterized by The Cancer Genome Atlas revealed amplification and mRNA over-expression of the DPP3 gene in tumors with high NRF2 activity but lacking NRF2 stabilizing mutations. We further show that tumor-derived mutations in KEAP1 are hypomorphic with respect to NRF2 inhibition and that DPP3 over-expression in the presence of these mutants further promotes NRF2 activation. Collectively, our findings further support the competition model of NRF2 activation and suggest that 'ETGE'-containing proteins like DPP3 contribute to NRF2 activity in cancer.
INTRODUCTION
Constitutive activation of the NF-E2-related factor 2 (NRF2) cap-n-collar transcription factor is emerging as a prominent molecular feature of many tumors. When active, NRF2 controls the expression of ~200 genes that collectively function to maintain a healthy intracellular reduction-oxidation (redox) balance, clear electrophilic xenobiotics, and degrade damaged and misfolded proteins (1, 2) . The leading hypothesis posits that whereas short-term NRF2 activation antagonizes oncogenesis by curtailing oxidative damage, constitutive activation promotes the survival of metabolically stressed cancer cells, as well as cancer cells under chemotherapeutic insult. Indeed, depletion of NRF2 from cancer-derived cell lines results in apoptosis and increased sensitivity to chemotherapeutic agents (3) . In human non-small cell lung cancer, tumors showing high levels of NRF2 protein are associated with a poor outcome and increased resistance to that the WTX tumor suppressor protein physically binds KEAP1 to competitively inhibit NRF2 ubiquitination (25) . Similarly, p62/SQSTM1, PALB2, and p21 bind KEAP1 or NRF2 to sterically inhibit NRF2 ubiquitination (26) (27) (28) . For WTX and PALB2, the association with KEAP1 is achieved through an ETGE motif, which mimics the NRF2 binding interface. As expected, these proteins activate NRF2-mediated transcription in the absence of oxidative stress, through ETGE-dependent competition with NRF2 for KEAP1 binding. Here, we sought to comprehensively define all ETGE or ESGE containing proteins within the KEAP1 protein interaction network, determine whether they functionally control NRF2 and evaluate their expression within human tumors, particularly in relation to NRF2 activity.
METHODS

Tissue Culture, Transfections, and Small Interfering RNAs
HEK293T and H2228 cells were obtained from the American Tissue and Culture Collection, which authenticates cells line using short tandem repeat analysis. Cell lines were not passaged for more than 6 months after resuscitation. HEK293T cells were grown in DMEM supplemented with 10% FBS and 1% GlutaMAX (Life Technologies) in a 37°C humidified incubator with 5% CO2. H2228 cells were grown in RPMI supplemented with 10% FBS. KEAP1 -/-mouse embryo fibroblasts (MEFs) were 
Affinity Pulldowns and Western Blotting
For Streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 lysis buffer. Cell lysates were cleared by centrifugation and incubated with streptavidin resin (GE Healthcare) or FLAG resin (Sigma) before washing with lysis buffer and eluting with NuPAGE loading buffer (Life Technologies). For siRNA, HEK293T cells were transiently transfected and lysed in RIPA buffer 60 h post-transfection. All antibodies and buffers used for Western analysis are listed in Supplemental Methods.
Plasmids, Expression Vectors, and Site-directed Mutagenesis
Expression constructs in the SBPHA backbone were generated with standard PCR techniques. Constructs for DPP3 and DPP3
Y318F
were a generous gift from Maja Abramić. The reporter gene fusion construct for human hNQO1-ARE-luciferase was a kind gift from Jeffrey Johnson. The SLK-HA construct was a generous gift from Dr. Andrey Cybulsky. Expression constructs for ETGE-containing proteins were obtained from Open Biosystems and cloned into a custom lentiviral vector (pHAGE-CMV-FLAG-DEST). ETGE deletion mutants were generated by PCR-based mutagenesis and sequence verified prior to use (GENEWIZ). For the assay depicted in Figure 6E , treatment with 50 μM tBHQ was performed 48 h post-transfection, and activation was measured 60 h post-transfection.
ARE-luciferase Quantification
on
Cell-based NRF2 ubiquitination experiments
HEK293T stably expressing SBPHA-KEAP1 cells were transfected with VSV-UB1, FLAG-NRF2, and SBPHA-DPP3. Venus-NPM1 was used such that each condition received the same mass of DNA. Cells were lysed in 0.1% NP-40 lysis buffer.
RNA Isolation, Reverse Transcription, and Semi-quantitative Real Time-PCR
Total RNA from cells was harvested in TRIzol (Life Technologies) reagent according to the manufacturer's instructions. RNA was quantified by UV spectrophotometry, and
Crystallographic Modeling
The coordinates for the KEAP1-NRF2 peptide complex and DPP3 were downloaded from the RCSB Protein Data Bank (PDB IDs 1X2R and 3FVY, respectively). The superposition of the ETGE motifs of NRF2 and DPP3 was done in PyMOL (The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC). PyMOL was used to prepare the images used in Figure 4D -G.
Affinity Purification and Mass Spectrometry
For Streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 lysis.
Cell lysates were incubated with Streptavidin or FLAG resin and washed 5X with lysis buffer. The precipitated proteins were trypsinized directly off beads using the FASP Protein Digestion Kit (Protein Discovery). For tandem purification of the FLAG-KEAP1 and SBPHA-DPP3 complex ( Figure 3B ), protein complexes were eluted after the first affinity purification with either 150 μg/μl FLAG peptide or 50 mM biotin.
Protein Identification, Filtering and Bioinformatics
Detailed methods for the mass spectrometry and peptide identification are provided in Supplemental Methods. Filtering of false interactions from non-tandem, wildtype experiments was accomplished using SPOTLITE, with an internal lab dataset of 158 Streptavidin experiments on 60 different baits, and using a 10% FDR for the entire dataset. FLAG-based APMS data were not scored with SPOTLITE because our FLAGspecific reference dataset is prohibitively small. Proteins identified in tandem or mutant experiments were accepted if they passed the SPOTLITE filtering on the non-tandem, Table S1 .
Motif Analysis
Identification of enriched 4-mer amino acid sequences was performed using a 1-tail Fisher's exact test (Table S2) . We individually tested each of the 13265 4-mer sequences present among the KEAP1 interactors, taking into account the number of interacting proteins, interacting proteins having the motif, total proteins in the UniProtKB/SwissProt database, and the total number of proteins having the motif within UniProtKB/SwissProt.
Bonferroni correction was applied due to multiple hypothesis testing.
Immunostaining
For subcellular localization of exogenously expressed proteins, cells were co-transfected with the indicated plasmids and plated on 10ug/ml fibronectin-coated coverslips. Cells were fixed in 4% paraformaldehyde in cytoskeletal buffer for 15 minutes, and coverslips were mounted to slides using the Prolong Gold antifade reagent (Molecular Probes). 
RESULTS
Proteomic analysis of the KEAP1 protein interaction network.
We defined the KEAP1 protein interaction network by affinity purification and shotgun mass spectrometry (APMS) ( Figure 1B ). In total, the KEAP1 complex was analyzed 13 times, where variations in affinity purification, detergent solubilization and cell treatment helped to maximize comprehensive network mapping (Table S1 ). True interactions were identified from false positives using SPOTLITE, a novel probabilistic scoring algorithm that couples direct and indirect data to identify false positive interactions within APMS data ( Figure 1B and Table S1 ) (manuscript under review). Of 42 high confidence KEAP1-interacting proteins identified, 17 contain an ETGE, ESGE or both. To determine if this motif is enriched within the KEAP1 protein interaction network (PIN) beyond chance observation, we performed a Fisher's exact test. The ETGE motif was identified as the only significant 4 amino acid sequence within the KEAP1 PIN (Table S2) .
Together, these data support and expand the 'ETGE' competition model of KEAP1 regulation.
The ETGE motif is required for binding to KEAP1.
We selected eight ETGE-containing proteins and validated their association with KEAP1 (Figure 2A-B) . Western blot analysis of affinity purified KEAP1 protein complexes Of the proteins tested, DPP3 and TSC22D4 strongly activated NRF2-mediated transcription in an ETGE-dependent manner, the former of which was previously identified as an activator of NRF2-dependent transcription in a gain-of-function screen (29) (Figure 2F ). Over-expression of SLK also activated NRF2-mediated transcription, although this activation was independent of the ETGE motif ( Figure S1 ).
DPP3 is a KEAP1 interacting protein.
The protein dipeptidyl peptidase III (DPP3) had the greatest impact on NRF2-dependent transcription and was the most abundant protein within the KEAP1 PIN ( Figure 2F and Table S1 , respectively) (30) . To further explore DPP3, we defined and compared the DPP3 PIN to the KEAP1 PIN ( Figure 3A interaction between KEAP1 and DPP3, the integrated PIN revealed no common interacting proteins. We also defined the PIN for DPP3 ΔETGE ; as expected KEAP1 was not observed (Table S1 ). To more rigorously characterize the KEAP1-DPP3 protein complex, we performed sequential affinity purifications for FLAG-KEAP1 and SBPHA-DPP3. Using HEK293T cells stably expressing both proteins, we purified FLAG-KEAP1 complexes and then from the resulting eluate, purified DPP3 with Streptavidin ( Figure 3B , top). The reciprocal sequential purification was done and analyzed by APMS ( Figure 3B , bottom). Despite observing over 1500 spectral counts representing each bait protein, the only protein identified in both APMS experiments was SQSTM1, represented by 15 and 1 total spectra, respectively ( Figure 3B and Table S1 ). Together these data argue that the KEAP1-DPP3 complex is largely exclusive from other interacting proteins.
We next tested whether endogenously expressed DPP3 and KEAP1 associate. First, endogenous DPP3 was detected within FLAG-KEAP1 affinity purified protein complexes from HEK293T cells ( Figure 3C ). Second, endogenous KEAP1 affinity purified with SBPHA-DPP3 ( Figure 3D ). Finally, we detected KEAP1 within immunopurified endogenous DPP3 protein complexes ( Figure 3E ). In addition to these studies in HEK293T cells, DPP3 was also detected within KEAP1 protein complexes isolated from H2228 lung cancer cells ( Figure 3F ). As protein complex purification is subject to post-lysis interactions, we determined if DPP3 and KEAP1 co-localized within cells. Although discrete subcellular localizations were not observed, exogenously expressed DPP3 co-localized with both exogenous and endogenous KEAP1 protein; (Table S1 ). Deletion of the ETGE motif within DPP3 may render the protein unstable and/or misfolded, which could account for lack of binding to KEAP1. To address this possibility, we tested the ability of a DPP3 alanine mutant to bind KEAP1.
Like DPP3
ΔETGE
, alanine point mutations within the domain (ETGEAAGE) abolished KEAP1 binding ( Figure 4D ). Crystallographic modeling revealed that NRF2 binds KEAP1 near the central pore of the KELCH β-propeller ( Figure 4E ) (10, 13, 32) . Using the crystal structure of DPP3, we asked if the ETGE motif within DPP3 and NRF2 adopt similar tertiary conformations.
The ETGE motif in DPP3 lies on an unstructured loop on the surface of the protein ( Figure 4F ) (33) . It is therefore in a sterically favorable position to bind to KEAP1, as opposed to being buried within the globular domains. Similar to the NRF2 peptide, three tyrosine residues and one phenylalanine residue defines the binding surface that accommodates the specific conformation of the ETGE peptide of DPP3 ( Figure 4G ). Strikingly, the ETGE motif of DPP3 and NRF2 adopt identical conformations when superimposed, suggesting that the ETGE motif of both proteins may interact with KEAP1 in a similar manner ( Figure 4H ) (root mean square deviation ≈ 0.05 Å between Cα atoms).
DPP3 competes with endogenous NRF2 for binding to KEAP1.
We tested whether DPP3 association with KEAP1 displaces NRF2. As homodimeric KEAP1 binds a single NRF2 molecule via two amino acid motifs ( Figure 1A) , competition experiments required the isolation of monomeric KEAP1. We created two double stable cell lines: the first expressed both SBPHA-KEAP1 and FLAG-KEAP1, and the second expressed SBPHA-KEAP1 and the FLAG-tagged BTB domain of KEAP1.
Sequential affinity purification with streptavidin and FLAG resins purified KEAP1 homodimer or a KEAP1-BTB "pseudo-monomer", allowing us to test whether DPP3 competes with NRF2 for KEAP1 binding ( Figure 5A ). Compared to a truncated form of WTX that does not interact with KEAP1 (25), DPP3 over-expression resulted in reduced NRF2 binding to the pseudo-monomer KEAP1 but not to the KEAP1 homodimer ( Figure   5B ; compare lanes 3 and 4 to lanes 7 and 8). In contrast, when DPP3 ΔETGE was introduced into each double-stable cell line, NRF2 binding to both the KEAP1-KEAP1 homodimer and KEAP1-BTB heterodimer was maintained ( Figure 5C ; compare lane 5 to 6). These findings suggest that DPP3 competes with NRF2 for binding to KEAP1 in an ETGE-dependent manner.
The 'hinge-and-latch' model predicts that loss of binding of the NRF2 DLG motif to KEAP1 results in a reduction of NRF2 ubiquitination and subsequent degradation. Given that DPP3 competes for binding to KEAP1 via the ETGE motif ( Figure 5A -C), we tested if DPP3 over-expression reduced NRF2 ubiquitination in an ETGE-dependent manner.
Affinity purification of exogenous NRF2 followed by Western blot analyses revealed relative levels of NRF2 ubiquitination. As the amount of wild-type DPP3 increased, ubiquitination of NRF2 decreased, as compared to control ( Figure 5D ; compare lanes 2 and 6). Consistent with its inability to bind KEAP1, DPP3 ΔETGE did not reduce NRF2 ubiquitination ( Figure 5E ). These data suggest that over-expression of DPP3 alters the architecture of NRF2 bound to dimeric KEAP1, and ultimately decreases NRF2 ubiquitination.
DPP3 activates NRF2 signaling in an ETGE-dependent fashion.
To establish functional significance of DPP3 as a regulator of NRF2 activity, we determined whether DPP3 gain-of-function and loss-of-function impacted NRF2 Figure 6A ). For loss-of-function, we designed and tested the silencing efficacy of three non-overlapping siRNAs targeting DPP3 ( Figure 6B ). siRNA-mediated silencing of DPP3 suppressed NRF2-mediated transcription of the ARE reporter, similar to that of NRF2 silencing ( Figure 6C ). To validate this phenotype using endogenous NRF2 readouts, qPCR was employed to monitor the expression of two well-established NRF2 target genes: heme oxgenase-1 (HMOX1) and glutamate-cysteine ligase modifier (GCSm). In agreement with the reporter data, DPP3 siRNAs reduced HMOX1 and GCSm transcript levels similar to that of NRF2 silencing ( Figure 6D) . Finally, the model predicts that DPP3 gain-of-function or loss-of-function would not affect NRF2 activity after treatment with a pathway agonist, as NRF2 would already be in a sterically unfavorable conformation for KEAP1-mediated ubiquitination and degradation ( Figure   1A ). Consistent with this hypothesis, neither DPP3 siRNAs ( Figure 6F ) nor overexpression of DPP3 ( Figure 6G ) were able to suppress NRF2-mediated transcription after treatment with the small molecule, tert-butylhydroquinone (tBHQ).
DPP3 expression and DNA copy number positively correlates with NRF2 activity in squamous cell lung cancer.
To establish physiological significance for DPP3 in controlling KEAP1-NRF2 signaling, we evaluated DPP3 mRNA abundance and gene alterations in squamous cell lung carcinoma, using data from the TCGA consortium (15) . First, we found that DPP3 mRNA expression is increased in lung SQCC as compared to matched normal tissue Figure 7A ). Of the four established lung SQCC subtypes, DPP3 expression is highest in primitive-type tumors ( Figure 7A and S2)(34). Second, DPP3 genomic copy number and mRNA expression positively correlated, suggesting that DPP3 gene amplification may drive DPP3 over-expression in lung SQCC ( Figure 7B) . Third, when segregated by genotype, DPP3 mRNA levels were higher in NRF2 wildtype lung SQCC as compared to tumors with mutated NRF2, which is consistent the proposed DPP3-competition model ( Figure 7C) . Surprisingly, DPP3 mRNA abundance was found to be increased in KEAP1 mutant tumors as compared to KEAP1 wildtype tumors ( Figure 7D ). This co-occurrence might be explained if the mutations in KEAP1 are hypomorphic, resulting in a partially compromised ability to suppress NRF2. If so, the presence of DPP3 may further drive NRF2 activity. To test this hypothesis, we cloned and expressed five distinct KEAP1 mutations from the TCGA lung SQCC dataset and evaluated their impact on NRF2 function. In both HEK293T cells and KEAP1-/-mouse embryo fibroblasts, all five KEAP1 mutants displayed reduced but not absent activity in suppressing NRF2, thus supporting the notion that these somatic mutations are hypomorphic ( Figure 7E and Figure S3 ). Impressively, over-expression of DPP3 further activated NRF2 in the presence of all five KEAP1 hypomorphs ( Figure 7F) . Importantly, the KEAP1 somatic mutants analyzed maintained association with both DPP3 and NRF2 ( Figure S3 ). These data support a model wherein somatic mutation of KEAP1 partially impairs its ability to suppress NRF2, and the presence of 'ETGE'-containing proteins like DPP3 may further drive pathway activity in KEAP1 mutant tumors. 
Finally, we tested whether DPP3 expression associated with NRF2 transcriptional activity across the lung SQCC cohort, as defined by the expression of a gene set signature consisting of 15 NRF2 target genes (3). DPP3 expression and the NRF2 signature score strongly associated ( Figure 7H ). Together, these data suggest that through competitive binding to KEAP1, DPP3 genomic amplification and over-expression may promote NRF2 activity in squamous cell carcinoma of the lung.
DISCUSSION
Aberrant KEAP1/NRF2 signaling has emerged as a critical regulatory pathway in a multitude of disease pathologies, most notably cancer. Although substantial progress has been made to define how reactive cysteines within KEAP1 govern its ability to ubiquitinate NRF2, the role of proteins peripheral to the KEAP1/NRF2/CUL3 core complex has only just begun to be explored. Recent studies have revealed four proteins that bind KEAP1 or NRF2 and ultimately inhibit NRF2 ubiquitination. Of these, WTX and PALB2 employ an ETGE motif to directly bind KEAP1, thus displacing and stabilizing NRF2. Given these discoveries and the likelihood that KEAP1-associated proteins contribute to NRF2 perturbation in human disease, particularly when genomic alterations within KEAP1 and NRF2 are lacking, we sought to establish the ETGE motif as a defining characteristic in KEAP1 associated proteins that functionally control NRF2 stability.
We found that the ETGE motif defines the most frequently observed four amino acid sequence within the KEAP1 protein interaction network (Table S2; Because it robustly activates NRF2-mediated transcription ( Figure 6A ), binds KEAP1 with near exclusivity ( Figure 3A and B) and has established catalytic activity, we chose to focus our mechanistic studies on DPP3. Although DPP3 possesses exopeptidase activity in vitro (33, 46), we were unable to reveal a role for its catalytic activity in either contributing to the KEAP1 interaction ( Figure 3D and 4C) or regulating NRF2-mediated transcription ( Figure 3I ). That said, our studies did not examine the temporal effects of DPP3 expression on NRF2 activity, but rather assessed pathway activity at steady-state. The ETGE motif of DPP3 resides in a flexible loop on the surface of the protein and adopts a similar conformation to the NRF2 ETGE peptide when bound to KEAP1 ( Figure   4F and G). Loss of this motif, either through deletion or point mutation, abrogates the KEAP1-DPP3 protein interaction (Figure 4) , perturbs the interaction between NRF2 and KEAP1 ( Figure 5 ), as well as alters NRF2 ubiquitination ( Figure 5 ). We interpret these data to support a model wherein DPP3 competes the low-affinity DLG motif of NRF2 off of the KEAP1 KELCH domain, resulting in a complex of KEAP1, DPP3, and NRF2.
Additional experiments are needed to determine protein stoichiometry within complexes containing KEAP1, NRF2, and DPP3. These experiments will reveal whether competitors like DPP3 specifically compete off the DLG of NRF2, as opposed to the ETGE motif; based on the relative affinities of the DLG and ETGE motifs, competition with the DLG motif of NRF2 is most probable (10, 11).
In cancer, over-expression of an ETGE-containing protein may promote NRF2 activity in the absence of inactivating KEAP1 mutations or activating NRF2 mutations. Indeed, high NRF2 activity in tumors lacking KEAP1 or NRF2 mutation has been reported in ovarian cancer, sarcoma and squamous cell lung cancer (5, 17, 47). After defining the ETGE-containing proteins within the KEAP1 protein interaction network (Figure 1 
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